Deep Brain Stimulation for Treatment-Resistant Obsessive Compulsive Disorder

NCT ID: NCT00057603

Last Updated: 2011-11-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-01-31
• Study Completion Date: 2009-07-31

Brief Summary

This study will evaluate the use of Deep Brain Stimulation (DBS) to reduce symptom severity and enhance the quality of life for patients with treatment-resistant obsessive compulsive disorder (OCD).

Detailed Description

Despite advances in pharmacological and behavioral therapies for OCD, a substantial number of patients fail to improve significantly following years of conventional and experimental interventions. For some patients, stereotactic neurosurgery is the only promising option available. Although this procedure has relatively few side effects in the majority of OCD patients and may lead to enduring benefits, its effects on brain tissue and function are irreversible. Bilateral deep brain stimulation (DBS) is an adjustable and partially reversible procedure that may be a more effective treatment for patients with OCD. This study will determine the effectiveness, safety, and tolerability of DBS in patients with treatment-refractory OCD.

Participants receive DBS treatment for 30 months. Obsessive Compulsive scales, depression scales, neuropsychological evaluations, and surveys are used to assess participants.

Participants are monitored for 2 years after DBS treatment.

Conditions

Obsessive-Compulsive Disorder

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Deep Brain Stimulation

Participants receive deep brain stimulation treatment for 30 months.

Group Type: EXPERIMENTAL

Deep Brain Stimulation

Intervention Type: PROCEDURE

Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.

Interventions

Deep Brain Stimulation

Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Intractable, malignant, and treatment refractory OCD that has caused substantial suffering and a reduction in the patient's psychosocial functioning for > 5 years
• Poor prognosis without neurosurgical intervention
• Failed an adequate trial of clomipramine and at least two of the following selective serotonin reuptake inhibitors (SSRIs): fluoxetine, fluvoxamine, citalopram, sertraline, and paroxetine. Additionally, patients must have failed augmentation treatment with at least one of the above drugs for 1 month with at least two of the following: clonazepam, haloperidol, risperidone, olanzapine, and gabapentin.
• Willingness to undergo augmentation treatment with a low-dose neuroleptic if tics are present prior to surgery
• Failed an adequate trial of cognitive behavioral therapy/exposure response prevention while taking clomipramine and an SSRI

Exclusion Criteria

• Current or lifetime Axis I diagnosis that substantially complicates function, treatment, or the subject's ability to comply with study procedures, or may lead to serious adverse events such as overdose, attempted suicide, or other potentially threatening behaviors
• Diagnosis and/or treatment for depression within the past year. Patients with a more distant history of depression will not be excluded.
• Previous neurosurgical procedure or AXIS III diagnosis of brain pathology
• Implants that contain electrical circuitry, generate electrical signals, and/or have metal parts
• Nonremovable body jewelry
• Anticoagulants or other medications that would put patients at risk for surgery-related complications
• Diathermy for physical therapy
• Pregnancy

• Minimum Eligible Age: 23 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Mental Health (NIMH)

NIH

Sponsor Role: collaborator

University of Florida

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Herbert Ward, MD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

University of Florida College of Medicine

Gainesville, Florida, United States

Countries

United States

References

Vora AK, Ward H, Foote KD, Goodman WK, Okun MS. Rebound symptoms following battery depletion in the NIH OCD DBS cohort: clinical and reimbursement issues. Brain Stimul. 2012 Oct;5(4):599-604. doi: 10.1016/j.brs.2011.10.004. Epub 2011 Nov 4.

Reference Type: DERIVED

PMID: 22305344 (View on PubMed)

Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Shapira NA, Wu SS, Hill CL, Rasmussen SA, Okun MS. Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol Psychiatry. 2010 Mar 15;67(6):535-42. doi: 10.1016/j.biopsych.2009.11.028. Epub 2010 Feb 8.

Reference Type: DERIVED

PMID: 20116047 (View on PubMed)

Other Identifiers

R21MH064161

Identifier Type: NIH

Identifier Source: secondary_id

View Link

DATR A5-ETMA

Identifier Type: -

Identifier Source: secondary_id

R21MH064161

Identifier Type: NIH

Identifier Source: org_study_id

View Link